Delandistrogene moxeparvovec-rokl (Elevidys; Sarepta Therapeutics) is currently approved to treat Duchenne muscular dystrophy in 4- and 5-year-old patients who have a confirmed DMD gene mutation.
In late December, Sarepta Therapeutics initiated filings with the FDA to expand the labeled indications for delandistrogene moxeparvovec-rokl (Elevidys), which uses adeno-associated virus–based gene transfer therapy to spur production of the dystrophin protein.1,2 The gene therapy was approved by the FDA in June 2023 and is the first such agent indicated to treat a specific patient population with Duchenne muscular dystrophy (DMD): ambulatory patients aged 4 to 5 years with a confirmed DMD gene mutation.3 The expanded indication seeks to remove the age limit.
The DMD space has seen much success in the past few years, with the FDA also approving Sarepta’s eteplirsen (Exondys 51), golodirsen (Vyondys 53), and casimersen (Amondys 45), as well as NS Pharma’s viltolarsen (Viltepso) in the past 6 years alone.4
This newest application from Sarepta constitutes an efficacy supplement of its biologics license application and it is supported by data from 2 pivotal clinical studies: EMBARK (NCT05096221), a phase 3 multinational, randomized, double-blind, placebo-controlled trial, and ENDEAVOR (NCT04626674), a phase 1 open-label trial. A priority review of the supplement has been requested, as has that delandistrogene moxeparvovec’s current accelerated approval change to traditional approval based on Sarepta’s submission of the postmarketing reuirement for EMBARK.
Traditional approval means approval that is based on data showing a proven clinical benefit, whereas accelerated approval is for treatments meant to fill an unmet clinical need and is based on surrogate markers from earlier in the clinical trial process, therefore providing earlier access to potentially life-saving treatments.5,6 However, the accelerated approval process has received criticism in recent years for purported lower regulatory standards and lack of due diligence.7
“Consistent with our patient commitment, Sarepta moved rapidly to submit an efficacy supplement to the biologics license application for Elevidys seeking label expansion to remove age and ambulation restrictions from the approved indication,” said Doug Ingram, president and CEO, Sarepta Therapeutics, in a statement. “Understanding that Duchenne patients are in a race against time, we appreciate that the Agency also moved quickly to engage and provide us with guidance on the process for reviewing our BLA supplement.”1
DMD is a genetic disorder with root causes in spontaneous or genetic mutations in the DMD gene and the mother’s X chromosome. This mutation subsequently affects production of the dystrophin protein, an element crucial to preventing muscle fiber breakdown from enzyme exposure and enabling normal muscle recovery.8,9
Sarepta is collaborating with Roche, which is tasked with regulatory approvals for the gene treatment outside of the United States, to bring delandistrogene moxeparvovec to patients worldwide living with DMD.
References
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More